U.S. Hospitality Stock News

NasdaqGS:PCAR
NasdaqGS:PCARMachinery

Assessing PACCAR (PCAR) Valuation After Q4 Revenue Beat And Softer Truck Market

Fourth quarter earnings reset expectations for PACCAR (PCAR) PACCAR (PCAR) is back in focus after its fourth quarter 2025 earnings, where sales of US$6,252.1 million and net income of US$556.9 million came in below the prior year but ahead of revenue forecasts. See our latest analysis for PACCAR. Despite the softer quarter, PACCAR’s share price has moved higher, with a 31.03% 90 day share price return and a 23.52% 1 year total shareholder return suggesting sentiment has improved rather than...
NYSE:UTI
NYSE:UTIConsumer Services

What Universal Technical Institute (UTI)'s Higher Sales But Lower Profit Reveals About Its Expansion Strategy

Universal Technical Institute, Inc. has reported past first-quarter 2026 results, with sales rising to US$220.84 million while net income fell to US$12.83 million compared with the previous year. This mixed update follows the company’s ongoing expansion in healthcare education through Concorde Career Colleges and new skilled trades programs, highlighting its push to broaden revenue sources even as profitability tightens. Next, we will examine how this combination of higher revenue but lower...
NYSE:BAH
NYSE:BAHProfessional Services

Is Booz Allen (BAH) Quietly Recasting Its Identity From Consultant To Cybersecurity Platform With Vellox Reverser?

Booz Allen Hamilton Holding recently launched Vellox Reverser, an AI-driven malware reverse engineering and threat intelligence product now broadly available to federal and commercial customers, while also expanding its role in Halcyon’s new Incident Response Partner Program alongside Beazley Security. The combination of automated malware analysis, historical campaign linkage, and integrated incident response positions Booz Allen more firmly as a full-spectrum cybersecurity solutions...
NasdaqGS:MDLZ
NasdaqGS:MDLZFood

Mondelez International (MDLZ) Margin Compression Challenges Defensive Snack-Narrative After Q4 2025 Results

Mondelez International (MDLZ) has wrapped up FY 2025 with fourth quarter revenue of US$10.5b and basic EPS of US$0.52, alongside net income of US$665m, setting the tone for how the full year is being judged. The company has seen quarterly revenue move from US$9.6b in Q4 2024 to US$10.5b in Q4 2025, while basic EPS shifted from US$1.31 to US$0.52 over the same period, giving investors a view of top line scale and per share profitability. With trailing net profit margins down over the past year...
NasdaqGS:CINF
NasdaqGS:CINFInsurance

Cincinnati Financial Dividend Hike And New Leaders Highlight Income Focus

Cincinnati Financial increased its quarterly dividend by 8%, marking its 66th consecutive year of dividend growth. The company announced new executive appointments in actuarial, reinsurance, and financial leadership roles. These updates highlight both shareholder returns and leadership changes at NasdaqGS:CINF. Cincinnati Financial, traded as NasdaqGS:CINF, recently reported a quarterly dividend increase alongside several leadership changes. The stock closed at $168.95, with a 1 year...
NasdaqCM:QUBT
NasdaqCM:QUBTTech

Assessing Quantum Computing (QUBT) Valuation After A Sharp Pullback From Multi Year Gains

Quantum Computing stock moves after recent trading performance Quantum Computing (QUBT) has come into focus after a sharp pullback, with the stock showing a 5.4% decline over the past day and double-digit negative returns over the past week and month. See our latest analysis for Quantum Computing. At a share price of $9.13, Quantum Computing’s recent pullback, with a 30.6% 90 day share price return decline, sits against a much stronger 3 year total shareholder return of more than 3.5x. This...
NasdaqGM:FRPT
NasdaqGM:FRPTFood

Is Freshpet (FRPT) Pricing Reflect Recent Share Slump And Premium Pet Food Growth Hopes

If you are wondering whether Freshpet stock is offering value at its current price, it helps to step back and look at what the recent share performance is really telling you. Freshpet shares last closed at US$69.20, with recent returns of 15.1% over 30 days and 15.0% year to date, set against a 7 day return of a 3.2% decline and a 1 year return of a 53.7% decline. Recent news flow around Freshpet has largely focused on its position in the premium pet food market and how investors are...
NYSE:WOLF
NYSE:WOLFSemiconductor

What Wolfspeed (WOLF)'s New AI-Focused Silicon Carbide Power Package Means For Shareholders

In late January 2026, Wolfspeed introduced its new TOLT silicon carbide power package portfolio for AI datacenter rack power supplies, designed to improve heat dissipation via top-side cooling and enable more compact, efficient systems. This launch highlights Wolfspeed’s role in supplying U.S.-based silicon carbide substrates for mission-critical infrastructure, aligning with efforts to bolster domestic semiconductor resilience for high-power AI and energy applications. Next, we’ll assess...
NYSE:HL
NYSE:HLMetals and Mining

Hecla Mining Weighs Quebec Asset Sale And Future Production Mix

Hecla Mining (NYSE:HL) has begun a review of its Quebec assets, including the option of a potential sale. The company is opening M&A discussions that could reshape its portfolio and operating footprint in Canada. This move follows recently reported annual production results and updated guidance for the coming periods. Hecla Mining is a North American focused precious metals producer with operations concentrated in silver and gold. The review of its Quebec portfolio comes at a time when...
NasdaqGS:AMGN
NasdaqGS:AMGNBiotechs

Is Amgen (AMGN) Offering Fair Value After Strong Multi Year Share Price Gains

If you are wondering whether Amgen's current share price gives you fair value for your money, this article will walk through what the numbers say and where valuation checks point your attention. With the stock at US$366.20, recent returns of 6.8% over 7 days, 10.9% over 30 days, 11.8% year to date, 27.0% over 1 year, 67.9% over 3 years, and 81.0% over 5 years put a spotlight on what investors are currently willing to pay for Amgen. Recent coverage around Amgen has focused on its position in...
NasdaqCM:SBET
NasdaqCM:SBETHospitality

Is It Time To Reassess Sharplink (SBET) After Recent Share Price Slide?

If you are wondering whether Sharplink's current share price reflects its true value, you are not alone. The stock's recent track record gives plenty to think about before making any decisions. Sharplink's share price last closed at US$7.08, after a 29% decline over the past week and a 31.1% decline over the past month. It is still sitting 40.5% higher than a year ago and remains well below its 3 year return of a 90.4% decline. Recent coverage around Sharplink has focused on its role in the...
NYSE:OWL
NYSE:OWLCapital Markets

Is Blue Owl Capital (OWL) Now Offering Value After Its Steep Share Price Decline

If you are wondering whether Blue Owl Capital’s current share price reflects good value, you are not alone. This article is designed to help you weigh what the numbers are really saying. The stock has recently been under pressure, with returns of a 16.8% decline over 7 days, a 24.0% decline over 30 days and a 21.2% decline year to date, on top of a 49.4% decline over the past year. This comes even though the 3 year and 5 year returns sit at 2.0% and 37.6% respectively. These moves have put...
NasdaqCM:SMPL
NasdaqCM:SMPLFood

Is Simply Good Foods (SMPL) Quietly Rewriting Its Governance Playbook With Scalzo’s Board Return?

After The Simply Good Foods Company’s 2026 Annual Meeting of Stockholders, the board appointed Joseph E. Scalzo as director to fill the vacancy created by Geoff E. Tanner’s mid-January departure, while shareholders approved a new equity incentive plan and re-elected ten directors and the auditor for fiscal 2026. This combination of leadership changes and a refreshed incentive plan highlights how Simply Good Foods is reshaping governance and executive incentives to align management and...
NYSE:F
NYSE:FAuto

Is It Too Late To Consider Ford Motor (F) After A 48% One-Year Share Price Rally?

If you are wondering whether Ford Motor's current share price still offers value, or if most of the easy gains are already on the table, this article walks through what the numbers say about the stock. Over the last year, Ford Motor's share price return is 48.3%, compared with 3.6% year to date and 2.6% over the last month. These moves may have shifted how some investors think about its growth potential and risk profile. Recent coverage around Ford Motor has focused on how the company is...
NasdaqGS:JKHY
NasdaqGS:JKHYDiversified Financial

Jack Henry And Associates (JKHY) Margin Improvement Challenges Slower Growth Narrative

Jack Henry & Associates (JKHY) just posted its Q2 2026 numbers, with revenue of US$619.3 million and basic EPS of US$1.72, alongside net income of US$124.7 million. The company has seen revenue move from US$573.8 million in Q2 2025 to US$619.3 million in Q2 2026, while basic EPS went from US$1.34 to US$1.72 over the same stretch. This performance is supported by trailing twelve month EPS of US$6.98 on revenue of US$2.5 billion, and highlights an increasingly important story about how margins...
NYSE:CSL
NYSE:CSLBuilding

Carlisle Companies (CSL) Margin Compression Challenges Bullish Earnings Narratives

Carlisle Companies (CSL) closed out FY 2025 with Q4 revenue of US$1,127.7 million and basic EPS of US$3.21, alongside net income excluding extra items of US$133.4 million. This gives investors a clear view of its core earnings power. Over the last six reported quarters, the company has seen quarterly revenue move between US$1,095.8 million and US$1,449.5 million, while basic EPS has ranged from roughly US$3.16 to US$5.93. This sets the backdrop for how the latest results fit into its recent...
NYSE:RMD
NYSE:RMDMedical Equipment

ResMed Builds Digital Sleep Apnea Ecosystem As Investors Track Valuation

ResMed (NYSE:RMD) is expanding its digital health ecosystem around sleep apnea diagnosis and treatment, supported by tools such as myAir, AirView, and Brightree. Recent developments in wearable screening devices and new FDA approvals are broadening access to sleep apnea testing and connecting more patients to ResMed's digital platform. Following a major competitor recall, ResMed has strengthened its position in the CPAP market, reinforcing its role in long-term respiratory care. For...
NYSE:MGM
NYSE:MGMHospitality

MGM Resorts (MGM) Margin Rebound In Q4 Challenges Bears On Profitability Concerns

MGM Resorts International (MGM) closed out FY 2025 with fourth quarter revenue of US$4.6 billion and basic EPS of US$1.10, alongside net income of US$293.6 million, putting a clean set of headline numbers in front of investors. Over recent quarters, the company has seen revenue move from US$4.3 billion in Q4 2024 to US$4.3 billion in Q1 2025, US$4.4 billion in Q2, US$4.3 billion in Q3 and back to US$4.6 billion in Q4. Quarterly basic EPS shifted from US$0.52 to US$0.52, US$0.18, a loss of...
NYSE:CWT
NYSE:CWTWater Utilities

California Water Service Group Gains Policy Seat While Valuation Signals Mixed Picture

California Water Service Group Chairman and CEO Marty Kropelnicki has joined the newly formed CalCEO Council. The council brings together 22 CEOs from across California to advise on statewide economic policy and community affordability. The move signals a broader policy role for California Water Service Group beyond its core utility operations. For you as an investor watching NYSE:CWT, this development puts the company in a more visible policy seat at the state level. With the share price...
NYSE:KVUE
NYSE:KVUEPersonal Products

Is It Time To Reconsider Kenvue (KVUE) After The Johnson & Johnson Spin Off?

Wondering whether Kenvue shares offer good value at around US$18.01, or if the price already reflects most of the story? This article walks through what the numbers say so you can decide how it fits your portfolio. Over the shorter term, Kenvue's share price return sits at 3.9% over 7 days and 7.1% over 30 days, while the year to date return is 4.0% and the 1 year return is a 9.6% decline. Recent headlines around Kenvue have focused on its position as a standalone consumer health company and...
NYSE:AMTM
NYSE:AMTMProfessional Services

A Look At Amentum Holdings (AMTM) Valuation After Recent Nuclear Contract Wins

Amentum Holdings (AMTM) is back in focus after a series of nuclear sector wins, including fresh contract awards with Electricite de France and new build planning work in the Netherlands, as well as involvement in a nuclear waste borehole demonstration. See our latest analysis for Amentum Holdings. Those nuclear wins have coincided with a sharp pickup in momentum, with a 90 day share price return of 67.28% and a 1 year total shareholder return of 60.71% from a last close of $36.45. Recent...
NYSE:NRP
NYSE:NRPOil and Gas

Does NRP’s “Fortress” Balance Sheet Goal and Carbon Storage Optionality Reshape Its Investment Narrative?

Natural Resource Partners L.P. has highlighted its ongoing progress toward a “fortress” balance sheet built around durable mineral assets, consistent free cash flow, and a target of US$30 million in cash with no permanent debt, a goal it had expected to reach within about a year at the time of the commentary. Beyond its extensive coal-focused mineral portfolio, the partnership also controls substantial unleased carbon sequestration pore space, which could provide an additional longer-term...
NasdaqGS:FORM
NasdaqGS:FORMSemiconductor

Is It Too Late To Consider FormFactor (FORM) After Its Strong Multi‑Year Share Price Run?

If you are wondering whether FormFactor’s share price still represents good value after a strong run, you are not alone. This article is designed to help you frame that question clearly. FormFactor closed at US$71.57 recently, with a 1.4% decline over the last week, a 14.2% gain over 30 days, a 20.9% return year to date, 74.1% over 1 year and 147.3% over 3 years. This naturally raises questions about what is already priced in. These moves sit against a backdrop of ongoing interest in...
NasdaqCM:MLTX
NasdaqCM:MLTXBiotechs

MoonLake Immunotherapeutics (MLTX) Is Down 7.5% After FDA Fast Track Nod For Sonelokimab In PPP – Has The Bull Case Changed?

Recently, MoonLake Immunotherapeutics reported that the FDA’s Dermatology Division granted Fast Track designation to sonelokimab for moderate-to-severe palmoplantar pustulosis, following supportive Phase 2 LEDA data, while analysts responded divergently to the company’s broader pipeline outlook after the past VELA-2 trial failure in hidradenitis suppurativa. This mix of accelerated regulatory attention for palmoplantar pustulosis and elevated approval risk for hidradenitis suppurativa puts...